Female Reproductive & Breast

HPV vaccination: counseling and schedule

Clinical Overview and When to Offer HPV Vaccination

— Bivalent and quadrivalent products are no longer distributed in the US

— Routine at age 11–12 (may start as early as age 9)

— Catch-up through age 26 for everyone not adequately vaccinated

— Shared clinical decision-making (SCDM) ages 27–45 — not routinely recommended; discuss individual risk of new HPV exposure (new/multiple partners, divorce, MSM, immunocompromise)

Human papillomavirus (HPV) is the most common sexually transmitted infection in the US, with >80% lifetime acquisition risk in sexually active adults

Oncogenic ("high-risk") types — especially HPV 16 and 18 — cause ~70% of cervical cancers and the majority of anal, vulvar, vaginal, penile, and oropharyngeal cancers

Low-risk types HPV 6 and 11 cause ~90% of anogenital warts and recurrent respiratory papillomatosis

Only one vaccine is currently available in the US: 9-valent HPV vaccine (Gardasil 9, 9vHPV), covering types 6, 11, 16, 18, 31, 33, 45, 52, 58

ACIP-recommended ages:

Indicated regardless of sex, gender identity, sexual orientation, or prior Pap/HPV testing results

Board pearl: A patient with a history of genital warts, abnormal Pap, positive HPV DNA, or treated CIN should still receive HPV vaccination if age-eligible — vaccination protects against types they have not yet acquired and may reduce recurrence after excisional treatment

Step 3 vignettes commonly test the 27–45 SCDM window: a 32-year-old recently divorced woman starting to date again is the classic "yes, offer it after discussion" stem

Vaccine is prophylactic, not therapeutic — does not clear existing HPV infection or treat existing dysplasia/warts

Step 3 family medicine framing: HPV vaccination is a primary cancer prevention intervention, alongside HBV vaccine, smoking cessation, and sun protection — frame counseling that way to parents who hesitate at "STI vaccine" language

Presentation Patterns and Key Counseling History

— Age and prior HPV vaccine doses (dates, product, number) — determines whether a 2-dose or 3-dose series applies

— Pregnancy status in postmenarchal patients — defer if pregnant

— Immunocompromise (HIV, transplant, B-cell deficiency, chemotherapy, chronic high-dose steroids) — mandates 3-dose schedule regardless of age at initiation

— Severe allergy to yeast (9vHPV is produced in Saccharomyces cerevisiae) or prior anaphylaxis to a HPV vaccine dose — contraindication

— Moderate or severe acute illness — defer; mild illness or low-grade fever is not a contraindication

— "Will it encourage sexual activity?" — multiple studies show no increase in sexual activity or earlier debut

— "She's not sexually active, why now?" — vaccine works best before exposure; immunogenicity is higher at ages 9–14, allowing a 2-dose schedule

— "Is it safe?" — >135 million doses distributed in the US; safety profile dominated by injection-site reactions and syncope

HPV vaccination is delivered in the context of a well-child visit, sports physical, college pre-matriculation visit, or adult preventive visit — the "presentation" is usually a scheduled encounter, not symptoms

Key history to elicit before vaccinating:

Common parental concerns to anticipate and address:

Key distinction: A history of a positive HPV test or abnormal cytology is not a contraindication and not a reason to skip vaccination — the patient is likely exposed to only one or two types

Step 3 management: When a parent declines, document the conversation, revisit at every subsequent visit (presumptive recommendation language: "Your child is due for three vaccines today — Tdap, meningococcal, and HPV"), and avoid prolonged debate that delays the rest of the visit

Pre-vaccination pelvic exam, Pap testing, or HPV DNA testing is not required prior to vaccination at any age

Physical Exam and Pre-Vaccination Assessment

— Vital signs, particularly temperature, to screen for moderate/severe acute illness

— General appearance — ill-appearing patients warrant deferral

— Injection site inspection (deltoid) — avoid areas with tattoos, infection, or significant scarring

— Mental status and anxiety level — adolescents are the highest-risk group for vasovagal syncope post-injection

— Intramuscular injection into the deltoid (or anterolateral thigh in smaller patients)

— 0.5 mL dose; needle length per patient size (typically 1–1.5 inch in adolescents/adults)

— Patient should be seated or lying down, and observed for 15 minutes post-injection to detect syncope

— Tdap, MenACWY, MenB, influenza, COVID-19 can all be given at the same visit

— Use separate injection sites (different limbs preferred) and document lot numbers individually

— Injection-site pain, erythema, swelling in 70–90%

— Low-grade fever, headache, myalgia, fatigue — typically <48 hours

— Self-limited; treat with acetaminophen or ibuprofen as needed

The pre-vaccination encounter is brief and focused — no genital exam is required or recommended before administering HPV vaccine

Essential pre-administration checks:

Administration technique:

Co-administration is permitted and encouraged:

Expected local exam findings post-vaccination (counsel the patient):

Board pearl: Syncope after adolescent vaccination is a tested patient-safety item — the seated/recumbent position with 15-minute observation is the standard of care to prevent fall-related head injury. A vignette describing an adolescent who stood up immediately, fainted, and struck their head is asking about this protocol gap

Document VIS (Vaccine Information Statement) provision date — federally required under the National Childhood Vaccine Injury Act

Dosing Schedule — 2-Dose vs 3-Dose Series

— Age 9 through 14 at first dose: 2-dose schedule — doses at 0 and 6–12 months (minimum interval 5 months between dose 1 and dose 2)

— Age 15 through 45 at first dose: 3-dose schedule — doses at 0, 1–2, and 6 months (minimum intervals: 4 weeks between dose 1 and 2, 12 weeks between dose 2 and 3, and 5 months between dose 1 and 3)

Schedule depends on age at initiation of the series, not current age:

Immunocompromised patients of any age (HIV, primary immunodeficiency, transplant, cancer treatment, chronic immunosuppression): always use the 3-dose schedule, even if started before age 15

Interrupted series: Do not restart the series regardless of interval between doses — simply give the remaining doses at the minimum intervals. There is no maximum interval

If a dose was given at less than the minimum interval, repeat the dose after a minimum interval has passed

Mixed-product series (someone who received earlier 4vHPV in another country, for example): complete the series with 9vHPV — count prior valid doses; do not restart

A patient who received 2 doses on the 2-dose schedule before age 15 is considered fully vaccinated even if the second dose was given after their 15th birthday — what matters is age at series initiation

Step 3 management: A 16-year-old presents having received one HPV dose at age 13. Because the series was initiated before age 15, only one more dose is needed (at least 5 months after dose 1) — not two more

Conversely: a 14-year-old who received dose 1 at age 14 and dose 2 just 3 months later — dose 2 is invalid (minimum interval 5 months on the 2-dose schedule); repeat the dose

Board pearl: The "age at first dose" rule is the most commonly missed scheduling concept. Memorize: <15 → 2 doses; ≥15 or immunocompromised → 3 doses; never restart

Special Scheduling Scenarios and Documentation

— Ideal candidates: new sexual partner anticipated, MSM, history of STI, immunocompromise, sex workers

— Less benefit: stable monogamous long-term relationship with no anticipated new exposures

— Vaccine name, manufacturer, lot number, expiration date

— Date administered, route, site, dose volume

— Name and title of administering clinician

— VIS edition date and date VIS was given to patient/guardian

— Entry into state/regional immunization information system (IIS) / registry

Catch-up vaccination is recommended through age 26 for everyone not adequately vaccinated — this is a routine, non-discretionary recommendation

Ages 27 through 45: Shared clinical decision-making (SCDM) — not routine, but may be offered after individualized discussion. Insurance coverage varies; many private plans and Medicaid cover SCDM-aged vaccination, but verify

Documentation requirements (under NCVIA):

Verification of prior doses: Accept written records, electronic medical records, IIS records, or self-report only when documented in a medical record — self-recall alone is generally not sufficient to count a dose

Vaccine storage: 9vHPV is stored refrigerated at 2–8°C (36–46°F); do not freeze. A frozen vial must be discarded

CCS pearl: Order set for adolescent well visit should bundle "HPV vaccine, dose [N] of [total]" with observe 15 minutes post-injection, VIS provided, and return to clinic in 6 months for next dose — these are the orders graders look for

Step 3 management: When records are unavailable and the patient cannot confirm prior vaccination, vaccinate as if unvaccinated — there is no harm in additional doses, and serologic testing for HPV is not validated for determining vaccination status

Address insurance: Vaccines for Children (VFC) program covers HPV vaccine through age 18 for Medicaid, uninsured, underinsured, and AI/AN children

Contraindications, Precautions, and Counseling Logic

— Severe allergic reaction (anaphylaxis) to a previous HPV vaccine dose

— Severe allergy to any vaccine component, notably yeast (9vHPV is yeast-derived)

— Moderate or severe acute illness with or without fever — vaccinate when recovered

— Pregnancy — defer remaining doses until postpartum; vaccine is not recommended in pregnancy though no harm has been demonstrated

— Breastfeeding — vaccinate normally

— Mild illness (URI, otitis media, low-grade fever, diarrhea)

— Immunocompromise — not a contraindication; in fact, vaccination is especially important (use 3-dose schedule)

— History of HPV infection, genital warts, abnormal Pap, CIN, or HPV-related cancer

— Family history of vaccine reaction

— Concurrent antibiotic use

— Egg allergy (not relevant to HPV vaccine)

— Hold remaining doses until after delivery

— No pregnancy termination or special monitoring is indicated for vaccine exposure

— Resume the series postpartum at the next scheduled dose — do not restart

— Pregnancy testing is not required before vaccination in routine settings

Absolute contraindications:

Precautions (defer, do not permanently contraindicate):

NOT contraindications (common distractors on exams):

If pregnancy occurs mid-series:

Key distinction: Pregnancy is a precaution, not a contraindication, but in practice it functions as a "defer" — distinguish from MMR/varicella, which are contraindicated in pregnancy because they are live vaccines. HPV vaccine is recombinant (subunit), not live — the deferral is precautionary, not biologic

Board pearl: A 22-year-old who received HPV dose 1, then discovers she is 8 weeks pregnant — counsel reassurance, do not give remaining doses during pregnancy, resume postpartum. Breastfeeding is fine to vaccinate.

Step 3 management: SCDM in ages 27–45 should explicitly document: discussion of risk of new HPV exposure, likely benefit given prior exposures, cost/coverage, and patient preference

Counseling Scripts and Addressing Hesitancy

— "Your child is due for three vaccines today: Tdap, meningococcal, and HPV"

— Avoid: "What do you want to do about the HPV vaccine?" (open-ended framing reduces uptake)

— Elicit specific concern → acknowledge → provide tailored information → ask permission to share recommendation

— Common concerns and responses:

— "Too young / not sexually active": "The vaccine works best before any exposure. Their immune response is also stronger at this age — that's why we only need two doses now instead of three later."

— "It's new / not enough data": "We have over 15 years of safety data and >135 million doses given. Countries that vaccinated early are already seeing >80% drops in cervical precancers."

— "Will it cause infertility / autoimmune disease?": "Large studies have looked specifically at this — no link found to infertility, POI, GBS, or autoimmune disease."

— "It encourages sex": "Studies show no change in sexual behavior or timing of first intercourse after vaccination."

— "This is one of only two vaccines we have that prevents cancer — HPV and hepatitis B"

— "It prevents cervical, anal, throat, and other cancers — in both boys and girls"

Presumptive (announcement) approach is evidence-based and increases vaccination rates:

If parent hesitates, use motivational interviewing:

Frame as cancer prevention, not STI prevention:

Boys: Emphasize prevention of oropharyngeal cancer (now the most common HPV-related cancer in US men), anal cancer, penile cancer, and reduced transmission to partners

Board pearl: The strongest predictor of HPV vaccine uptake is a clear, presumptive provider recommendation — exam vignettes test that the right next step when a parent is "unsure" is a strong recommendation with specific cancer prevention framing, not deferral to "think about it"

Step 3 management: If the parent still declines, document, schedule next visit, and revisit at every encounter — many families accept after 2–3 conversations

Efficacy, Population Impact, and Co-Interventions

— >95% against persistent infection with vaccine types

— >95% against high-grade cervical, vulvar, vaginal, and anal precancers caused by vaccine types

— ~90% against genital warts

— 88% reduction in cervical HPV 16/18 infections among vaccinated women in the US

— >80% reduction in CIN 2+ in highly vaccinated populations (Scotland, Australia)

— Australia projects cervical cancer elimination (<4/100,000) by ~2035 with continued vaccination + screening

— Herd immunity observed in unvaccinated women and in MSM

— Vaccinated individuals should follow standard age-based screening (USPSTF/ACS):

— Ages 21–29: cytology alone every 3 years (USPSTF) — note ACS now recommends HPV testing starting at 25

— Ages 30–65: HPV testing alone every 5 years (preferred), or co-testing every 5 years, or cytology every 3 years

— Screening stops at 65 if adequate prior negative screening

— Condom use (reduces but does not eliminate transmission)

— Smoking cessation (smoking is a cofactor for cervical cancer progression)

— Limiting number of sexual partners

— HIV prevention/treatment

Efficacy of 9vHPV against vaccine-type disease in HPV-naïve recipients:

Real-world impact (post-vaccination era data):

HPV vaccine does NOT replace cervical cancer screening:

Co-interventions for comprehensive HPV-related cancer prevention:

Key distinction: Vaccination + screening are complementary, not redundant — the vaccine does not cover all oncogenic types, and screening catches what the vaccine misses. Both are required for optimal prevention

Board pearl: A 30-year-old fully HPV-vaccinated woman asks if she still needs Pap testing — yes, follow standard screening guidelines. Skipping screening because of vaccination is a tested error

Step 3 management: Bundle adolescent prevention: HPV + Tdap + MenACWY + annual flu + risk-reduction counseling (sexual health, substance use)

Special Populations — Immunocompromised Patients

— HIV infection (any CD4 count)

— Solid organ or hematopoietic stem cell transplant recipients

— Primary immunodeficiency (B-cell, T-cell, complement, phagocyte disorders)

— Active malignancy or recent chemotherapy

— Chronic high-dose corticosteroids (≥20 mg/day prednisone equivalent ≥14 days) or other immunosuppressants (anti-TNF, rituximab, etc.)

— Asplenia is not a specific indication change for HPV (unlike some bacterial vaccines)

— Vaccinate at routine ages with 3-dose schedule

— No CD4 threshold required, but immunogenicity is better when virologically suppressed

— HIV+ patients have higher risk of persistent HPV infection, anal cancer (especially MSM with HIV), and cervical cancer — vaccination is high-priority

— Anal cancer screening (anal cytology ± HRA) is recommended in HIV+ MSM ≥35 and HIV+ others ≥45 per IDSA 2024 — vaccination does not replace this

All immunocompromised patients age 9–45 should receive HPV vaccine on a 3-dose schedule (0, 1–2, 6 months) — regardless of age at initiation

Conditions defining "immunocompromised" for HPV vaccination purposes:

HIV-specific considerations:

Transplant recipients: Ideally vaccinate before transplant when possible (better immunogenicity); if post-transplant, still vaccinate but expect attenuated response

Rheumatologic / IBD patients on biologics: Vaccinate; consider timing relative to rituximab (response is poor for ~6 months post-rituximab)

Board pearl: A 13-year-old with newly diagnosed HIV needs 3 doses, not 2, despite being under 15 — immunocompromise overrides the age-based 2-dose rule

Step 3 management: For a patient about to start chemotherapy, complete vaccination before starting if time permits; otherwise defer to ≥3 months after completion of immunosuppressive therapy for adequate response — but do not withhold indefinitely

HPV vaccine is inactivated/recombinant, so it is safe in immunocompromise — unlike MMR, varicella, LAIV, or yellow fever

Special Populations — Pregnancy, Adolescents, MSM, Survivors

— HPV vaccine is not recommended during pregnancy (precaution)

— No evidence of harm from inadvertent administration; no intervention if given during pregnancy beyond holding remaining doses

— Postpartum and breastfeeding women can and should be vaccinated if age-eligible and incomplete

— Pregnancy testing is not required before routine vaccination

— Optimal age 11–12; may start at 9

— Earlier vaccination → better immunogenicity → 2-dose schedule + completion before sexual debut

— Address confidentiality: in most US states, adolescents can consent to STI-related care, but HPV vaccine consent rules vary by state — many require parental consent; some states allow minor consent for HPV specifically

— Routinely vaccinate through age 26; SCDM through 45

— Lower herd protection from female-only vaccination eras → individual vaccination especially important

— High burden of anal HPV and anal cancer, particularly with HIV coinfection

— Higher risk of HPV-related malignancy

— Vaccinate per immunocompromised schedule (3 doses) if on/recently completed therapy

— Still vaccinate if age-eligible — protects against types not yet acquired

— Some evidence of reduced recurrence of CIN 2+ after excisional treatment in vaccinated patients

Pregnancy:

Adolescents (the target population):

Men who have sex with men (MSM):

Transgender and gender-diverse patients: Vaccinate per age-based guidelines regardless of gender identity or anatomy

Cancer survivors (especially childhood cancer):

Patients with prior HPV-related disease (genital warts, CIN, VIN, AIN, HPV+ oropharyngeal cancer):

Key distinction: Pregnancy = defer; immunocompromise = vaccinate with 3 doses; prior HPV disease = vaccinate as usual. Confusing these is a common exam trap

Step 3 management: A 25-year-old woman with newly diagnosed CIN 2 on colposcopy who is unvaccinated — recommend LEEP/excision and HPV vaccination; do not delay either

Adverse Effects and Safety Surveillance

— Injection site pain, erythema, swelling

— Headache, fatigue, low-grade fever, myalgia

— Usually self-limited within 24–48 hours

— Nausea, dizziness

— Local hematoma

— Syncope — especially in adolescents within 15 minutes of injection; can cause fall-related head injury

— Anaphylaxis — ~1.7 per million doses

— Injection-site cellulitis (very rare)

— Guillain-Barré syndrome

— Multiple sclerosis or other demyelinating disease

— Primary ovarian insufficiency / infertility

— POTS (postural orthostatic tachycardia syndrome)

— Complex regional pain syndrome

— Autism

— Sudden death

— VAERS (Vaccine Adverse Event Reporting System) — passive, anyone can report; clinician-mandated reporting for any event listed on the VAERS table or any event the manufacturer's package insert says to report

— VSD (Vaccine Safety Datalink) — active surveillance via integrated health systems

— CISA (Clinical Immunization Safety Assessment) — expert consultation for complex cases

Common (>10%):

Less common:

Rare but important:

NOT causally linked to HPV vaccination despite media claims (large epidemiologic studies):

Safety surveillance systems (know these for Step 3 public health questions):

VICP (Vaccine Injury Compensation Program): No-fault federal program; HPV vaccine is on the covered list. Patients with alleged vaccine injury file with US Court of Federal Claims within 3 years of symptom onset

Board pearl: A patient develops a transient brachial plexopathy after HPV vaccination — clinician must report to VAERS and inform the patient about VICP as the legal avenue for compensation (not a malpractice suit against the clinician)

Step 3 management: After vaccination, observe seated for 15 minutes to prevent syncope-related injury — this is the single most testable patient-safety step

When to Escalate, Consult, or Refer

— Anaphylaxis within minutes of injection — give IM epinephrine 0.3 mg (0.15 mg in children <30 kg) into the anterolateral thigh, repeat q5–15 min as needed, supplemental O2, IV fluids, transport to ED

— Severe syncope with head injury — assess for concussion, C-spine; CT head if signs of significant trauma

— Allergy/Immunology — for patients with history of severe reaction to a prior dose or to a vaccine component; may perform skin testing and graded dose challenge in a monitored setting

— Infectious disease / HIV specialist — for complex immunocompromised patients where timing relative to therapy is uncertain

— Oncology — to coordinate timing of vaccination around chemotherapy or transplant

— Maternal-fetal medicine — generally not needed for inadvertent vaccination in pregnancy; reassurance and deferral suffice

— VAERS for serious adverse events (death, hospitalization, permanent disability, life-threatening illness, congenital anomaly)

— Outbreaks of vaccine-preventable disease in vaccinated populations → state health department

— Wrong dose, wrong vaccine, wrong patient, expired vaccine, or improper storage exposure → disclose to patient, report to VAERS if adverse event occurred, revaccinate if dose was invalid, report to state IIS for tracking

HPV vaccination is overwhelmingly an outpatient primary care intervention — escalation is rare but high-yield when it occurs

Immediate escalation (call 911 / activate emergency response):

Specialty consultation:

Public health reporting:

When to involve risk management / patient safety:

CCS pearl: For anaphylaxis after vaccine in a clinic, the order sequence is: IM epinephrine → call 911 → place supine with legs elevated → O2 → IV access → IV fluids → consider H1/H2 blockers and steroids as adjuncts (not first-line) — epinephrine is always first

Step 3 management: A vaccine was stored at room temperature for 12 hours — contact the manufacturer or state immunization program for viability; if invalid, revaccinate and disclose — patient safety mandates transparency

Differentials — Conditions Confused with Vaccine Reactions

— Vasovagal syncope (most common) — pallor, diaphoresis, bradycardia, rapid recovery when supine — distinguish from anaphylaxis (which has urticaria, wheeze, hypotension, tachycardia)

— Anaphylaxis — urticaria, angioedema, bronchospasm, hypotension; treat with epinephrine

— Anxiety / hyperventilation — perioral and digital paresthesias, tachypnea, normal vitals

— Injection-site reaction vs cellulitis — vaccine reactions are usually within 24–48h, do not progress, no fever spike, no lymphangitic streaking

— Viral illness coincidental to vaccination — URI, gastroenteritis

— Migraine triggered by transient inflammatory response

— New menstrual irregularity in adolescent → consider normal anovulatory cycles, pregnancy, PCOS, thyroid disease, eating disorder — not HPV vaccine (no causal link to POI or menstrual disorders)

— Fatigue, joint pain → consider mononucleosis, viral arthritis, autoimmune onset, hypothyroidism

— Syncope on standing → POTS workup (orthostatic vitals, tilt-table if needed) — POTS is not caused by HPV vaccine but may present in same demographic

— Vaccine does not cause warts and does not treat existing infection — these represent pre-existing exposure that was incubating, not vaccine failure

— Counsel: vaccine still protects against types not yet acquired

— Vaccine does not cover all oncogenic HPV types (covers 9 of ~14 high-risk types)

— Vaccine does not clear existing infection

— Follow standard ASCCP management algorithms

When a patient presents with symptoms after recent HPV vaccination, do not anchor on the vaccine — consider:

Within minutes to 1 hour:

Hours to days:

Weeks later (often misattributed):

Genital warts appearing after vaccination:

Abnormal Pap in a vaccinated patient:

Key distinction: Vasovagal syncope vs anaphylaxis is the most tested differential in this space — bradycardia + pallor = vagal, tachycardia + urticaria + wheeze = anaphylaxis (give epinephrine)

Board pearl: A teenager's new "fatigue" weeks after HPV vaccine almost never represents a vaccine adverse event — workup for mono, depression, thyroid, anemia is the right path

Differentials — Other Preventive Decisions to Distinguish

— Tdap: Single dose at 11–12, then Td/Tdap every 10 years

— MenACWY: Dose at 11–12, booster at 16

— MenB: SCDM ages 16–23 (preferred 16–18), 2-dose series

— Influenza: Annual

— COVID-19: Per current ACIP schedule

— HPV: 2 or 3 doses depending on age at initiation

— Vaccination is primary prevention (before exposure)

— Screening is secondary prevention (detect precancer/early cancer)

— Both required; one does not replace the other

— HPV DNA testing is a screening/diagnostic tool, not a vaccination decision tool

— Do not order HPV testing before vaccinating — it does not change the recommendation

— Genital warts: podofilox, imiquimod, sinecatechins, cryotherapy, TCA, excision

— CIN 2+: LEEP, cold-knife conization, ablation

— HPV+ oropharyngeal cancer: surgery, radiation, chemoradiation

— Vaccine plays no role in treatment

— Both are the two recombinant vaccines that prevent cancer (cervical/anal/oropharyngeal vs hepatocellular carcinoma)

— Useful framing in counseling

— Through 26: routine recommendation — just offer

— 27–45: discussion required, document shared decision

HPV vaccine vs other adolescent vaccines (commonly confused on Step 3 vignettes):

HPV vaccination vs cervical cancer screening:

HPV vaccination vs HPV testing for clinical care:

HPV vaccination vs treatment of HPV disease:

HPV vaccine vs hepatitis B vaccine as "cancer-preventing vaccines":

Distinguishing the SCDM zone (27–45) from routine catch-up (through 26):

Key distinction: Step 3 often tests sequencing — vaccinate first, screen on schedule, treat disease when detected. These are parallel tracks, not alternatives

Step 3 management: A 24-year-old with new abnormal Pap and never vaccinated — manage the Pap per ASCCP AND vaccinate (still age-eligible for routine catch-up); the two decisions are independent

Board pearl: Vaccination decisions for HPV are age- and exposure-history based, not test-result-based

Long-Term Plan and Integration with Lifetime Prevention

— No booster doses currently recommended — durability of protection appears to be at least 10–15 years with no waning detected

— No serologic testing to confirm immunity (no validated correlate of protection assay)

— Document series completion in the state immunization registry and patient's portable record (especially important before college, international travel, military, healthcare worker onboarding)

— Start at age 21 (USPSTF) or 25 (ACS)

— Continue through age 65 with adequate prior negative screening

— Same intervals as unvaccinated patients — vaccination does not extend screening intervals (yet)

— HIV+ MSM ≥35, HIV+ others ≥45, HIV-negative MSM ≥45, women with history of high-grade vulvar/cervical lesions, solid organ transplant recipients — consider anal cytology and/or high-resolution anoscopy per local protocols

— Sexual health: number of partners, condom use, STI screening per CDC guidelines

— Smoking cessation — smoking accelerates HPV-related carcinogenesis

— HIV testing and PrEP consideration in at-risk patients

— Encourage vaccination of all eligible siblings

— Reinforce that both sexes benefit — boys equally, and herd protection improves with high coverage

— Adolescents transitioning to adult primary care: ensure completed vaccination status is communicated in the transfer summary

— College students: many require proof of HPV vaccination or recommend it on entry

After completion of HPV vaccine series:

Continue age-appropriate cervical cancer screening:

Anal cancer screening considerations (for patients at elevated risk):

Ongoing risk-reduction counseling at preventive visits:

For families:

Transition of care:

Step 3 management: At every preventive visit, run a vaccine reconciliation: check immunization registry, identify gaps (HPV, Tdap, flu, COVID, MenACWY, MenB), and address in one bundled discussion

Board pearl: A fully vaccinated 30-year-old asks if she can stop Pap testing — no, continue per standard guidelines until 65 with adequate negative history

Follow-Up, Monitoring, and Counseling Cadence

— No labs, no imaging, no special monitoring required

— Schedule the next dose at minimum interval

— Provide written reminder; many systems use automated patient portal recalls or text reminders — proven to improve completion rates

— Dose 2: 6–12 months after dose 1 (2-dose schedule) or 1–2 months after dose 1 (3-dose schedule)

— Dose 3 (if applicable): 6 months after dose 1 (and ≥12 weeks after dose 2)

— No post-completion follow-up specific to HPV vaccine is required

— Immunization registry reconciliation

— Updated sexual history

— Cervical cancer screening status (when age-eligible)

— Other preventive services per USPSTF

— Pre-vaccination: VIS provided, allergies reviewed, contraindications checked, consent documented

— Post-vaccination: Expected side effects, when to call, 15-minute observation

— Series completion: Update record, congratulate patient, transition to age-appropriate screening conversation

— HEDIS Immunizations for Adolescents (IMA) measure — % of 13-year-olds who completed HPV series (along with Tdap, MenACWY)

— Healthy People 2030 target: 80% completion of HPV series by age 15

— Practices are incentivized via value-based payment to hit these benchmarks — relevant to family medicine system-level questions

— Watch for severe injection-site reaction, persistent fever >48 hours, signs of allergy

— Most can manage with rest, hydration, acetaminophen/ibuprofen

Between doses:

Routine follow-up cadence:

Document and discuss at every well visit:

Counseling touchpoints:

Quality measures (relevant to Step 3 health systems questions):

Patient self-monitoring at home:

CCS pearl: "Schedule return appointment in 6 months for HPV dose 2" + "Update immunization registry" are both expected orders after a first-dose adolescent encounter

Step 3 management: For incomplete series in an established patient, do not order a workup — simply schedule and administer the next dose at minimum interval. Avoid the trap of "check titers first"

Ethical, Legal, and Patient Safety Considerations

— State laws vary on whether minors can consent to HPV vaccination independently of parents

— Most states require parental consent for minors

— Some states (e.g., a handful with specific statutes) allow minors to consent to STI-related care, which has been interpreted to include HPV vaccine in select jurisdictions

— A few states have explicit minor consent for HPV vaccine

— Always document who consented, what was discussed, and that the VIS was provided (federally required)

— Document the refusal, the discussion, and that you offered again

— Do not dismiss the family from the practice based solely on HPV refusal (ethically discouraged; AAP supports continued engagement)

— Revisit at every subsequent visit

— Some adolescents may request HPV vaccination without parental knowledge — handle per state law and clinic policy

— Be aware that insurance billing (EOB) may inadvertently disclose to parents

— VAERS reporting is required for any event listed on the VAERS Table of Reportable Events or specified in the vaccine's package insert (per the National Childhood Vaccine Injury Act)

— Failure to report is a regulatory violation

— HPV vaccine is covered; injured patients file in the US Court of Federal Claims within 3 years of symptom onset (or 2 years of death)

— This is a no-fault alternative to civil litigation

— Wrong dose, wrong vaccine, expired product, improper storage, missed dose timing — disclose, document, report to state immunization program, revaccinate if invalid

— VFC program covers vaccine for Medicaid-eligible, uninsured, underinsured, and AI/AN children through age 18

— Lower uptake in rural and uninsured populations → systems-level interventions (school-based clinics, standing orders, pharmacy-administered vaccines) improve access

Informed consent / assent:

Parental refusal:

Adolescent confidentiality:

Mandatory reporting:

Vaccine Injury Compensation Program (VICP):

Patient safety events to disclose transparently:

Equity considerations:

Board pearl: Documentation of the VIS date and lot number is federally mandated under NCVIA — not optional

Step 3 management: If a parent refuses, do not discharge the family, document the conversation, and address again at next visit — this is the ethically and clinically correct approach

High-Yield Associations and Rapid-Fire Facts

HPV 16 and 18 → ~70% of cervical cancers; HPV 6 and 11 → ~90% of genital warts

9vHPV covers: 6, 11, 16, 18, 31, 33, 45, 52, 58

Routine age: 11–12 (may start at 9)

Catch-up: through 26 (routine); 27–45 (SCDM)

2-dose schedule (0, 6–12 mo): first dose at ages 9–14

3-dose schedule (0, 1–2, 6 mo): first dose at ≥15 OR immunocompromised at any age

Minimum intervals: 4 wk (1→2), 12 wk (2→3), 5 mo (1→3); for 2-dose: 5 mo between doses

Never restart a series, regardless of interval

Yeast allergy = contraindication (vaccine produced in S. cerevisiae)

Pregnancy = defer; breastfeeding = OK

Immunocompromise = vaccinate, use 3-dose schedule

Prior HPV/CIN/warts = still vaccinate if age-eligible

No pre-vaccination HPV testing or Pap required

No post-vaccination titers or booster

Observe 15 minutes post-injection (syncope prevention)

VIS must be provided and date documented (NCVIA)

VAERS for adverse event reporting; VICP for compensation

Cancer prevention framing outperforms STI framing in parental counseling

Presumptive recommendation language ("She's due for three vaccines today") improves uptake

Most common HPV-related cancer in US men: oropharyngeal

Most common HPV-related cancer in US women: cervical

Australia/Scotland data: >80% reduction in high-grade cervical precancers

Continue Pap/HPV screening in vaccinated patients per standard guidelines

HEDIS IMA measure: completion of HPV + Tdap + MenACWY by age 13

Healthy People 2030: 80% completion of HPV series by age 15

VFC program: covers HPV vaccine for eligible children through age 18

Co-administration with Tdap, MenACWY, MenB, flu, COVID = safe and recommended

Anaphylaxis treatment: IM epinephrine 0.3 mg anterolateral thigh, repeat q5–15 min

Vasovagal vs anaphylaxis: bradycardia/pallor vs tachycardia/urticaria/wheeze

Board pearl: "Age at first dose <15 = 2 doses" is the single most testable scheduling fact

Board Question Stem Patterns

Stem 1 — Scheduling trap: "A 14-year-old received HPV dose 1 last year. He is now 15. How many more doses does he need?" → One more (series initiated <15 → 2-dose schedule; age at completion irrelevant). Distractor: "two more"

Stem 2 — Immunocompromised override: "A 13-year-old with HIV is starting HPV vaccination. What is the recommended schedule?" → 3 doses (0, 1–2, 6 mo), not 2, because of immunocompromise

Stem 3 — Pregnancy mid-series: "A 23-year-old received HPV dose 1, now finds she is 10 weeks pregnant. Next step?" → Defer remaining doses until postpartum; no special monitoring

Stem 4 — SCDM age: "A 35-year-old recently divorced woman with a new partner asks about HPV vaccine. Best response?" → Engage in shared clinical decision-making and offer vaccination if she elects after discussion of risks/benefits

Stem 5 — Prior HPV disease: "A 22-year-old with history of treated genital warts asks if vaccine is still useful. Best response?" → Yes, vaccinate — protects against types not yet acquired and may reduce recurrence

Stem 6 — Hesitant parent: "Parent of an 11-year-old declines HPV citing 'too young.' Best response?" → Strong presumptive recommendation framed as cancer prevention, with revisit at next visit; do not dismiss from practice

Stem 7 — Adverse event: "Adolescent develops urticaria, wheeze, hypotension 5 minutes post-injection. First step?" → IM epinephrine 0.3 mg in anterolateral thigh

Stem 8 — Syncope prevention: "Teen stood up immediately after HPV injection, fainted, hit her head. What protocol gap caused this?" → Failure to observe seated/recumbent for 15 minutes

Stem 9 — Storage error: "Vaccine was left at room temperature 14 hours. Next step?" → Do not administer; consult manufacturer/state program; revaccinate if dose was given and is invalid; disclose to patient

Stem 10 — Screening myth: "Fully HPV-vaccinated 30-year-old asks if she can skip Pap testing. Best response?" → No; continue routine cervical cancer screening per guidelines

Stem 11 — Allergy: "Patient reports severe yeast allergy. HPV vaccine recommendation?" → Contraindicated

Stem 12 — Documentation: "What is federally required at the time of vaccine administration?" → Provide and document VIS, lot number, manufacturer, date, site, route, administrator

Board pearl: Step 3 emphasizes the counseling response and next management step, not biology — choose the answer that addresses the parent/patient and moves care forward

One-Line Recap

High-yield bullet recaps:

HPV vaccination is a routine cancer-prevention intervention recommended for all individuals starting at ages 11–12 (and as early as 9), as catch-up through age 26, and as shared clinical decision-making through age 45 — with a 2-dose schedule if the series is initiated before age 15 and a 3-dose schedule if initiated at age 15 or older or in immunocompromised patients of any age, using 9-valent vaccine (Gardasil 9).

Schedule: <15 at first dose → 2 doses (0, 6–12 mo); ≥15 or immunocompromised → 3 doses (0, 1–2, 6 mo); never restart a series regardless of interval

Counseling: Use presumptive recommendation language and frame as cancer prevention ("prevents cervical, anal, throat, and other cancers"); address hesitancy with motivational interviewing and revisit at every visit if declined — do not dismiss from practice

Special situations: Pregnancy = defer; breastfeeding = vaccinate; immunocompromise = vaccinate with 3-dose schedule; prior HPV/warts/CIN = still vaccinate if age-eligible; yeast anaphylaxis = contraindicated

Safety and systems: Observe seated 15 minutes post-injection to prevent syncope-related injury; provide and document VIS (NCVIA-required); report serious adverse events to VAERS; injured patients access VICP; continue routine cervical cancer screening in vaccinated patients — vaccination does not replace screening, and screening does not replace vaccination

Step 3 management mantra: Vaccinate early, complete the series, screen on schedule, treat disease when detected — these are parallel preventive tracks that together drive HPV-related cancer toward elimination